You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
NameThyrotropin Alfa
Accession NumberDB00024  (BIOD00020, BTD00020)

Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cancer. It is a heterodimeric glycoprotein comprised of two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues containing one N-linked glycosylation site. The alpha subunit is nearly identical to that of human chorionic gonadotropin (hCG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). The alpha subunit is thought to be the effector region responsible for stimulation of adenylate cyclase (involved the generation of cAMP). The beta subunit (TSHB) is unique to TSH, and therefore determines its receptor specificity. The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone.

Protein structureDb00024
Protein chemical formulaC975H1513N267O304S26
Protein average weight22672.9000
>Alpha chain
>Beta chain
Download FASTA Format
rTSHNot AvailableNot Available
Thyroid stimulating hormoneNot AvailableNot Available
Thyrotrophin-alfaNot AvailableNot Available
Thyrotrophin-alphaNot AvailableNot Available
ThyrotropinNot AvailableNot Available
Thyrotropin-aNot AvailableNot Available
Thyrotropin-alphaNot AvailableNot Available
ThytrophinNot AvailableNot Available
TSHNot AvailableNot Available
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Thyrogeninjection, powder, for solution.9 mg/mLintramuscularGenzyme Corporation1998-11-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Thyrogenpowder for solution0.9 mgintramuscularGenzyme Canada A Division Of Sanofi Aventis Canada Inc2002-08-12Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
CAS number9002-71-5
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available
IndicationFor detection of residueal or recurrent thyroid cancer
PharmacodynamicsBinding of thyrotropin alfa to TSH receptors on normal thyroid epithelial cells or on well-differentiated thyroid cancer tissue stimulates iodine uptake and organification. Thyrogen is an exogenous source of human TSH that offers an additional diagnostic tool in the follow-up of patients with a history of well-differentiated thyroid cancer.
Mechanism of actionThyrotropin Alfa binds to the thyrotropin receptors found on any residual thyroid cells or tissues. This stimulates radioactive iodine uptake for better radiodiagnostic imaging.
AbsorptionTime to peak: Median: 10 hours (range: 3-24 hours) After a single intramuscular injection of 0.9 mg of thyrotropin alfa: Cmax= 116+38mU/L, Tmax=22+8.5 hours. AUC=5088+1728 mU·hr/L.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationkidney and liver
Half life25 ± 10 hours
ClearanceNot Available
ToxicityNo difference in efficacy and toxicity between adult and geriatric patients. No studies in lactating women, pregnant women and pediatrics. Cautionary administration is advised.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
  • Sanofi aventis us llc
  • Genzyme corp
Dosage forms
Injection, powder, for solutionintramuscular.9 mg/mL
Powder for solutionintramuscular0.9 mg
Unit descriptionCostUnit
Thyrogen 1.1 mg vial1196.4USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
CountryPatent NumberApprovedExpires (estimated)
United States58405661995-11-242015-11-24
Experimental Properties
melting point55 °CNot Available
hydrophobicity-0.330Not Available
isoelectric point7.50Not Available
Synthesis Reference


General References
  1. Lexicomp
    #Product label
External Links
ATC CodesH01AB01
AHFS Codes
  • 36:60.00
PDB Entries
FDA labelDownload (2.27 MB)
MSDSNot Available
Drug InteractionsNo interactions found.
Food InteractionsNot Available


1. Thyrotropin receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: agonist


Name UniProt ID Details
Thyrotropin receptor P16473 Details


  1. Szkudlinski MW: Recombinant human thyrotropins of the twenty-first century. Expert Opin Pharmacother. 2004 Dec;5(12):2435-40. Pubmed
  2. Conway GS: Clinical manifestations of genetic defects affecting gonadotrophins and their receptors. Clin Endocrinol (Oxf). 1996 Dec;45(6):657-63. Pubmed
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

comments powered by Disqus
Drug created on June 13, 2005 07:24 /Updated on October 14, 2014 17:27